I-Mab Q4 2025 Earnings Report

I-Mab EPS Results

• Actual EPS: -$0.30
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

I-Mab Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

I-Mab Announcement Details

• Quarter: Q4 2025
• Date: 4/8/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

I-Mab (NASDAQ:NBP) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs. The company’s strategy includes progressing internally discovered assets toward registration and exploring partnerships or licensing arrangements to expand commercial and geographic reach.

I-Mab’s capabilities are built around biologics research, including antibody discovery and protein engineering, translational development and clinical operations. The organization pursues a pipeline approach that balances oncology and immunology projects, aiming to generate data that can support regulatory submissions and potential commercialization either independently or with collaborators.

As a publicly listed company on U.S. markets, I-Mab communicates clinical progress and corporate developments through regulatory filings and public disclosures. Investors and industry observers typically monitor its clinical milestones, regulatory interactions and partnership activity as indicators of the company’s development trajectory. I couldn’t find enough reliable public information to provide detailed leadership names or an exhaustive list of individual product candidates without risking inaccuracy.